Prohibition on copay accumulator adjustments.
SB 435 prohibits the use of copay accumulator adjustments for prescription drugs in several Indiana health coverage arrangements. Under the bill, when a covered person or someone paying on their behalf pays for a prescription drug, that amount must count toward the person’s out-of-pocket maximum or other cost-sharing requirement. The bill applies to the state employee health plan, pharmacy benefit managers, insurers issuing accident and sickness policies, and health maintenance organizations, but only for plans, policies, or contracts established, entered into, amended, delivered, or renewed after June 30, 2025.
The bill also creates a limited exception for originating brand-name drugs when a generic alternative exists. In those cases, the accumulator prohibition does not apply unless the covered person obtained the brand-name drug through prior authorization, step therapy, or the applicable exceptions and appeals process. The bill defines “generic alternative” as an FDA-designated therapeutically equivalent drug that is nationally available.
SB 435 would amend multiple sections of the Indiana Code governing state employee health benefits and private health insurance to require that third-party payments for prescription drugs count toward deductible and out-of-pocket limits. This would affect plan administrators, pharmacy benefit managers, insurers, HMOs, state employees, insureds, and enrollees by reducing the extent to which copay assistance or other outside payments can be excluded from cost-sharing tallies. The bill is intended to limit copay accumulator programs and could accelerate members reaching their cost-sharing caps.
The available record shows no committee testimony, vote totals, or recorded debate, so there is no direct evidence of support or opposition from the legislative process in the materials provided. Based on the bill text, the measure appears consumer-protective and aimed at lowering prescription drug cost burdens for covered individuals. Its structure suggests an effort to balance that goal with utilization-management tools by preserving exceptions for prior authorization, step therapy, and appeals processes.
The main policy tension is between consumer advocates, who would favor counting copay assistance toward out-of-pocket limits, and insurers, pharmacy benefit managers, and plan administrators, who may view the bill as restricting cost-management practices. A second point of contention is the exception for brand-name drugs with available generics: the bill limits the prohibition in those cases unless the patient has gone through prior authorization, step therapy, or appeals. That carveout may be seen as preserving formulary controls while still protecting access in medically justified situations.